 Fatty Liver
"Fatty Liver" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.
| Descriptor ID |
D005234
|
| MeSH Number(s) |
C06.552.241
|
| Concept/Terms |
Steatohepatitis- Steatohepatitis
- Steatohepatitides
- Steatosis of Liver
- Visceral Steatosis
- Steatoses, Visceral
- Steatosis, Visceral
- Visceral Steatoses
- Liver Steatosis
- Liver Steatoses
- Steatoses, Liver
- Steatosis, Liver
|
Below are MeSH descriptors whose meaning is more general than "Fatty Liver".
Below are MeSH descriptors whose meaning is more specific than "Fatty Liver".
This graph shows the total number of publications written about "Fatty Liver" by people in this website by year, and whether "Fatty Liver" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 | | 2000 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 1 | 0 | 1 | | 2004 | 2 | 0 | 2 | | 2005 | 3 | 1 | 4 | | 2006 | 2 | 0 | 2 | | 2007 | 5 | 1 | 6 | | 2008 | 4 | 2 | 6 | | 2009 | 8 | 4 | 12 | | 2010 | 2 | 3 | 5 | | 2011 | 8 | 4 | 12 | | 2012 | 12 | 1 | 13 | | 2013 | 14 | 4 | 18 | | 2014 | 8 | 1 | 9 | | 2015 | 5 | 0 | 5 | | 2016 | 2 | 2 | 4 | | 2017 | 4 | 0 | 4 | | 2018 | 4 | 1 | 5 | | 2019 | 1 | 1 | 2 | | 2020 | 2 | 1 | 3 | | 2021 | 5 | 0 | 5 | | 2022 | 2 | 0 | 2 | | 2023 | 3 | 0 | 3 | | 2024 | 3 | 5 | 8 | | 2025 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Fatty Liver" by people in Profiles.
-
Cohen CC, Dabelea D, Davy BM, Glueck DH, Newton KP, Perng W, Welsh JA, Schwimmer JB, Vos MB. Responsiveness of the Serum Carbon Isotope Ratio to Dietary Added Sugar Reduction in a Randomized Controlled Trial among Youth with Steatotic Liver Disease. J Nutr. 2025 Oct; 155(10):3496-3505.
-
Lindsay M, Arndt G, Wieland A, Jensen T. Evolving Role of GLP-1 Therapies in Liver Disease. Curr Gastroenterol Rep. 2025 Jun 06; 27(1):36.
-
Ditzenberger GL, Lake JE, Kitch DW, Kantor A, Muthupillai R, Moser C, Belaunzaran-Zamudio PF, Brown TT, Corey K, Landay AL, Avihingsanon A, Sattler FR, Erlandson KM. Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study. Clin Infect Dis. 2025 02 24; 80(2):389-396.
-
Huneault HE, Lo JS, Bai S, He Z, McPhaul MJ, Bril F, Vos MB, Cree MG. Fasting intact insulin by mass spectrometry is associated with metabolic dysfunction-associated steatotic liver disease in youth. Hepatol Commun. 2024 Dec 01; 8(12).
-
Bonet J, Weiss R, Galderisi A, Dalla Man C, Caprio S, Santoro N. Adipose tissue insulin resistance in children and adolescents: linking glucose and free fatty acid metabolism to hepatic injury markers. Am J Physiol Endocrinol Metab. 2024 Dec 01; 327(6):E723-E728.
-
Schenker RB, Machle CJ, Allayee H, Lurmann F, Patterson WB, Kohli R, Goran MI, Alderete TL. Ambient air pollution exposure is associated with liver fat and stiffness in Latino youth with a more pronounced effect in those with PNPLA3 genotype and more advanced liver disease. Ecotoxicol Environ Saf. 2024 Nov 01; 286:117234.
-
Burtis AEC, DeNicola DMC, Ferguson ME, Santos RG, Pinilla C, Kriss MS, Orlicky DJ, Tamburini BAJ, Gillen AE, Burchill MA. Ag-driven CD8 + T cell clonal expansion is a prominent feature of MASH in humans and mice. Hepatology. 2025 Feb 01; 81(2):591-608.
-
Danpanichkul P, Suparan K, Dutta P, Kaeosri C, Sukphutanan B, Pang Y, Kulthamrongsri N, Jaisa-Aad M, Ng CH, Teng M, Nakano M, Morishita A, Alkhouri N, Yang JD, Chen VL, Kim D, Fallon MB, Diaz LA, Arab JP, Mantzoros CS, Noureddin M, Lazarus JV, Wijarnpreecha K. Disparities in metabolic dysfunction-associated steatotic liver disease and cardiometabolic conditions in low and lower middle-income countries: a systematic analysis from the global burden of disease study 2019. Metabolism. 2024 Sep; 158:155958.
-
Akhverdyan N, Wieland A, Sullivan S, Lindsay M, Swartwood S, Arndt G, Kaizer LK, Jensen T. Changes in Transient Elastography with Glucagon-Like Peptide-1 Receptor Agonist Use in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Real-World Retrospective Analysis. Metab Syndr Relat Disord. 2024 Oct; 22(8):608-618.
-
Lake JE, Kitch DW, Kantor A, Muthupillai R, Klingman KL, Vernon C, Belaunzaran-Zamudio PF, Fichtenbaum CJ, Heath S, Perazzo H, Corey K, Brown TT, Landay A, Sattler F, Erlandson KM. The Effect of Open-Label Semaglutide on Metabolic Dysfunction-Associated Steatotic Liver Disease in People With HIV. Ann Intern Med. 2024 06; 177(6):835-838.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|